Travere Therapeutics Inc (NASDAQ: TVTX) kicked off on Monday, down -3.41% from the previous trading day, before settling in for the closing price of $21.98. Over the past 52 weeks, TVTX has traded in a range of $5.12-$25.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 13.83% over the last five years. While this was happening, its average annual earnings per share was recorded 71.26%. With a float of $85.70 million, this company’s outstanding shares have now reached $87.45 million.
The firm has a total of 385 workers. Let’s measure their productivity. In terms of profitability, gross margin is 84.29%, operating margin of -169.03%, and the pretax margin is -171.4%.
Travere Therapeutics Inc (TVTX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Travere Therapeutics Inc is 1.53%, while institutional ownership is 111.15%. The most recent insider transaction that took place on Feb 12 ’25, was worth 122,356. In this transaction SENIOR VICE PRESIDENT, R&D of this company sold 5,200 shares at a rate of $23.53, taking the stock ownership to the 98,519 shares. Before that another transaction happened on Feb 12 ’25, when Company’s SVP, GC & CORPORATE SECRETARY sold 8,000 for $23.53, making the entire transaction worth $188,240. This insider now owns 89,482 shares in total.
Travere Therapeutics Inc (TVTX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 71.26% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
Take a look at Travere Therapeutics Inc’s (TVTX) current performance indicators. Last quarter, stock had a quick ratio of 2.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.10, a number that is poised to hit -0.54 in the next quarter and is forecasted to reach 0.84 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
Analysing the last 5-days average volume posted by the [Travere Therapeutics Inc, TVTX], we can find that recorded value of 1.81 million was better than the volume posted last year of 1.64 million. As of the previous 9 days, the stock’s Stochastic %D was 37.93%. Additionally, its Average True Range was 1.32.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 66.31%, which indicates a significant increase from 22.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.68% in the past 14 days, which was higher than the 59.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.66, while its 200-day Moving Average is $13.90. Now, the first resistance to watch is $22.00. This is followed by the second major resistance level at $22.78. The third major resistance level sits at $23.50. If the price goes on to break the first support level at $20.51, it is likely to go to the next support level at $19.79. Should the price break the second support level, the third support level stands at $19.02.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
The company with the Market Capitalisation of 1.85 billion has total of 78,050K Shares Outstanding. Its annual sales at the moment are 145,240 K in contrast with the sum of -111,400 K annual income. Company’s last quarter sales were recorded 62,900 K and last quarter income was -54,810 K.
